The invention provides methods and pharmaceutical compositions for
administering a PPAR.alpha. agonist (e.g., OEA-like agonist, OEA-like
compound), an OEA-like appetite reducing compound, or a FAAH inhibitor
and a CB1 cannabinoid receptor antagonist to a subject in order to reduce
the consumption or ingestion of food, ethanol or other appetizing
substances as well as in treating appetency disorders related to the
excess consumption of food, ethanol, and other appetizing substances. The
combination therapy can also be useful for reducing body fat or body
weight and modulating lipid metabolism.
